Alexion Pharmaceuticals, Inc.
METHODS FOR TREATMENT OF REFRACTORY GENERALIZED MYASTHENIA GRAVIS WITH ECULIZUMAB

Abstract:

The disclosure provides methods of treating refractory myasthenia gravis (MG) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5). In certain embodiments, the substance that specifically binds C5 is a binding protein, such as an anti-C5 antibody. In certain embodiments, the patient achieves and maintains the status of improved or MM according to the MGFA Post-Intervention Status.